Is Prostate-Specific Antigen Velocity Selective for Clinically Significant Prostate Cancer in Screening?
GROUND: The value of prostate-specific antigen velocity (PSAV) in screening for prostate cancer (PCa) and especially for clinically significant PCa is unclear. OBJECTIVE: To assess the value of PSAV in screening for PCa. Specifically, the role of PSAV in lowering the number of unnecessary biopsies and reducing the detection rate of indolent PCa was evaluated. DESIGN, SETTING, AND PARTICIPANTS: All men included in the study cohort were participants in the European Randomized Study of Screening for Prostate Cancer (ERSPC), Rotterdam section. INTERVENTION: During the first and second screening round, a PSA test was performed on 2217 men, and all underwent a biopsy during the second screening round 4 yr later. MEASUREMENTS: PSAV was calculated and biopsy outcome was classified as benign, possibly indolent PCa, or clinically significant PCa. RESULTS AND LIMITATIONS: A total of 441 cases of PCa were detected, 333 were classified as clinically significant and 108 as possibly indolent. The use
Related Questions
- Would prostate cancer detected by screening with prostate-specific antigen develop into clinical cancer if left undiagnosed?
- Is Prostate Specific Antigen Velocity Selective For Clinically Significant Prostate Cancer In Screening?
- Is Prostate-Specific Antigen Velocity Selective for Clinically Significant Prostate Cancer in Screening?
